Ganomycin I
Ganomycin I is a non-competitive dual inhibitor of α-glucosidase and HMG-CoA reductase, with IC50 values of 0.3 μM and 12.3 μM, respectively. Ganomycin I inhibits HIV-1 protease, with an IC50 of 7.5 μg/mL. Ganomycin I also suppresses RANKL-induced osteoclast differentiation and bone resorption by inhibiting the activation of ERK, JNK and p38 MAPK, as well as downregulating the c-Fos/NFATc1 signaling pathway. Ganomycin I exhibits antibacterial activity against Gram-positive bacteria, and shows weak activity against Mycobacterium tuberculosis H37Ra. It can be used in research related to metabolic diseases, bone metabolism and anti-infection.
For research use only. We do not sell to patients.
- CAS No.: 1191255-15-8
- Formula: C21H26O4
- Molecular Weight:342.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
α‑glucosidase 0.38 μM (IC50, rat small intestinal mucosa) |
α‑glucosidase 0.3 μM (IC50, Baker's yeast) |
α‑glucosidase 0.4 μM (IC50, rat small intestinal mucosa) |
HMG-CoA reductase 12.3 μM (IC50) |
HIV-1 Protease 7.5 μg/mL (IC50) |
In Vitro
Ganomycin I inhibits Baker's yeast α-glucosidase and rat small intestinal mucosa α-glucosidase with IC50 values of 0.3 μM and 0.4 μM, respectively; it also inhibits rat intestinal sucrase and maltase with IC50 values of 67.6 μM and 3.6 μM, respectively[3].
Ganomycin I (3-30 μM; 6 days) inhibits RANKL-induced osteoclastogenesis in mouse bone marrow macrophages (BMMs) in a dose-dependent manner by reducing the number of mature osteoclasts and downregulating the expression of the osteoclast marker proteins c-Src and CtsK[2].
Ganomycin I (3-30 μM; 4 days) inhibits RANKL-induced osteoclast formation in mouse RAW264.7 cells in a dose-dependent manner[2].
Ganomycin I (3-30 μM; 72 h) increases the cell viability of mouse bone marrow macrophages (BMMs) after incubation at concentrations of 3, 10, and 30 μM for 72 h, indicating that its anti-osteoclastogenic activity does not originate from cytotoxicity[2].
Ganomycin I (3-30 μM; 7 days) dose-dependently inhibits RANKL-induced bone resorptive activity in mouse bone marrow macrophages (BMMs) cultured on OsteoAssay Surface plates[2].
Ganomycin I (3-30 μM; 7 days) dose-dependently inhibits RANKL-induced actin ring formation in mouse bone marrow macrophages (BMMs), where actin ring serves as a marker of mature osteoclasts[2].
Ganomycin I (3-30 μM; pretreated prior to RANKL stimulation) dose-dependently inhibits RANKL-induced activation of ERK, JNK and p38 MAPKs, as well as the downstream expression of c-Fos and NFATc1, without affecting the activation of the NF-κB pathway in mouse RAW264.7 cells[2].
Ganomycin I (3-30 μM; pretreated prior to RANKL stimulation) dose-dependently inhibits RANKL-induced nuclear translocation of NFATc1 in mouse RAW264.7 cells[2].
Ganomycin I (3-30 μM; 4 days) dose-dependently reduces the expression of RANKL-induced NFATc1 target genes DC-STAMP, OSCAR, MMP-9 and TRAP in mouse bone marrow-derived macrophages (BMMs)[2].
Ganomycin I (compound 2) shows no activity against porcine pancreatic lipase[5].
Ganomycin I (50 μg/mL) exhibits no cytotoxicity toward non-malignant Vero cells[6].
Ganomycin I exhibits cytotoxicity against E-PR293 cells, so its anti-HIV-1 protease activity cannot be determined in this cell system[4].
Ganomycin I inhibits recombinant HIV-1 protease expressed in E. coli, with an IC50 of 7.5 µg/mL, and forms hydrogen bonds with the Asp30 residue at the active site of this enzyme[7].
Ganomycin I exhibits weak activity against Mycobacterium tuberculosis H37Ra with an MIC of 50 μg/mL; its MIC values against Gram-positive bacteria Bacillus cereus, Enterococcus faecium and Staphylococcus aureus are 25, 25 and 12.5 μg/mL, respectively[6].
Ganomycin I inhibits HMG-CoA reductase with an IC50 of 12.3 μM[3].
Ganomycin I exhibits non-competitive inhibition against both α-glucosidase and HMG-CoA reductase; kinetic assays use Ganomycin I at 0.3-1 μM for α-glucosidase detection and 5-20 μM for HMG-CoA reductase detection[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:mouse BMMs
-
Concentration:3, 10, 30 μM
-
Incubation Time:72 h
-
Result:Did not decrease cell viability of BMMs.
Increased cell viability at the tested concentrations.
-
Cell Line:mouse RAW264.7 cells
-
Concentration:3, 10, 30 μM
-
Incubation Time:10 min, 15 min,24 h, 48 h, 4 d
-
Result:Significantly decreased RANKL-induced phosphorylation levels of ERK, JNK, and p38 MAPKs in a concentration-dependent manner.
Attenuated RANKL-induced expression of c-Fos and NFATc1.
Did not block RANKL-induced degradation of IκBα.
-
Cell Line:mouse RAW264.7 cells
-
Concentration:30 μM
-
Incubation Time:48 h
-
Result:Significantly suppressed RANKL-induced nuclear translocation of NFATc1.
-
Cell Line:mouse BMMs
-
Concentration:3, 10, 30 μM
-
Incubation Time:4 days
-
Result:Significantly inhibited the expression of DC-STAMP, OSCAR, MMP-9, and TRAP genes in a concentration-dependent manner during RANKL-induced osteoclastogenesis.
In Vivo
Ganomycin I (1-5 mg/kg; p.o.; daily; 21-28 days) exerts potent hypoglycemic, hypolipidemic, insulin-sensitizing, and serum AST-lowering effects in KK-Ay mice; the insulin-sensitizing efficacy of the 5 mg/kg dose is superior to that of thiazolidinedione insulin sensitizers, both doses increase hepatic glycogen levels after 4 weeks of administration, and no reduction in serum ALT levels is observed[3].
No obvious abnormalities in behavior, feces and urine, convulsions, sleep or coma are observed, and no deaths are recorded within the 24 h and subsequent 14-day observation period after a single oral dose of Ganomycin I up to 3 g/kg[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (male; 8 weeks old; high-fat diet-induced obesity)[1]
-
Dosage:3.0 mg/kg
-
Administration:p.o.; daily; 5 weeks
-
Result:Exhibited similar efficacy to compound 7d in improving hyperglycemia and hyperlipidemia in diet-induced obese mice.
-
Animal Model:8-week-old insulin-resistant male KK-Ay mice; C57BL/6J normal control[3]
-
Dosage:1, 5 mg/kg
-
Administration:p.o.; daily; 21 days
-
Result:Reduced fasting/free-feeding glucose and HbA1c.
Improved OSTT, OGTT, ITT, serum insulin and ISI.
Reduced NEFA, TG, TC and LDL-C.
Increased hepatic glycogen.
Decreased AST.
Improved hepatic steatosis and reduced WAT adipocyte size.
Chemical Information
-
CAS No. 1191255-15-8
-
Molecular Weight 342.43
-
Formula C21H26O4
-
SMILES
OC1=C(C=C(C=C1)O)[C@@]2([H])C=C(C(O2)=O)CC/C=C(C)/CC/C=C(C)/C
-
Structure Classification
-
Initial Source
Ganoderma colossum
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
-
Osteoclast differentiation from monocyte/macrophage precursors
Osteoclast differentiation is an in vitro induction assay in which monocyte/macrophage-lineage precursors are exposed to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), generating multinucleated osteoclasts that are commonly identified by tartrate-resistant acid phosphatase (TRAP) staining and functionally confirmed by resorption pits on dentin, bone, or mineralized substrates. M-CSF supports survival and expansion of osteoclast precursors, while RANKL binding to RANK drives osteoclast commitment, fusion, maturation, and resorptive function; osteoprotegerin inhibits this pathway by binding RANKL and preventing RANK activation. The main readouts are the number of TRAP-positive multinucleated cells, formation of F-actin rings, and resorbed surface area; TRAP-positive multinucleated cells indicate osteoclast differentiation, whereas pit formation on dentin, bone, or mineralized coating indicates functional bone-resorbing activity.
Purity & Documentation
References
[1]. Wang K, et al. Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo. Journal of medicinal chemistry. 2018 Apr 26;61(8):3609-3625. [Content Brief]
[2]. Tran PT, et al. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2019 Mar 01;55:1-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)